Smith & Nephew PLC
LSE:SN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Smith & Nephew PLC
Stock-Based Compensation
Smith & Nephew PLC
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Smith & Nephew PLC
LSE:SN
|
Stock-Based Compensation
$43m
|
CAGR 3-Years
2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Stock-Based Compensation
$36.3m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Stock-Based Compensation
£1.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Inspiration Healthcare Group PLC
LSE:IHC
|
Stock-Based Compensation
£49k
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
EMV Capital PLC
LSE:EMVC
|
Stock-Based Compensation
£43k
|
CAGR 3-Years
-40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
|
Smith & Nephew PLC
Glance View
Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.
See Also
What is Smith & Nephew PLC's Stock-Based Compensation?
Stock-Based Compensation
43m
USD
Based on the financial report for Dec 31, 2025, Smith & Nephew PLC's Stock-Based Compensation amounts to 43m USD.
What is Smith & Nephew PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
11%
Over the last year, the Stock-Based Compensation growth was 7%. The average annual Stock-Based Compensation growth rates for Smith & Nephew PLC have been 2% over the past three years , 11% over the past five years .